Core-binding factor influences the disease specificity of Moloney murine leukemia virus

被引:27
作者
Lewis, AF
Stacy, T
Green, WR
Taddesse-Heath, L
Hartley, JW
Speck, NA [1 ]
机构
[1] Dartmouth Med Sch, Dept Biochem, Hanover, NH 03755 USA
[2] Dartmouth Med Sch, Dept Microbiol, Hanover, NH 03755 USA
[3] NIAID, Viral Dis Lab, Bethesda, MD 20205 USA
关键词
D O I
10.1128/JVI.73.7.5535-5547.1999
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The core site in the Moloney murine leukemia virus (Moloney MLV) enhancer was previously shown to be an important determinant of the T-cell disease specificity of the virus. Mutation of the core site resulted in a significant shift in disease specificity of the Moloney virus from: T-cell leukemia to erythroleukemia. We and others have since determined that a protein that binds the core site, one of the core-binding factors (CBF) is highly expressed in thymus and is essential for hematopoiesis. Here we test the hypothesis that CBF plays a critical role in mediating pathogenesis of Moloney MLV in vivo. We measured the affinity of CBE for most core sites found in MLV enhancers, introduced sites with different affinities for CBF into the Moloney MLV genome, and determined the effects of these sites on viral pathogenesis. We found a correlation between CBF affinity and the latent period of disease onset, in that Moloney MLVs with high-affinity CBF binding sites induced leukemia following a shorter latent period than viruses with lower-affinity sites. The T-cell disease specificity of Moloney MLV also appeared to correlate with the affinity of CBF for its binding site. The data support a role for CBF in determining the pathogenic properties of Moloney MLV.
引用
收藏
页码:5535 / 5547
页数:13
相关论文
共 86 条
[1]   Stability of AML1 (core) site enhancer mutations in T lymphomas induced by attenuated SL3-3 murine leukemia virus mutants [J].
Amtoft, HW ;
Sorensen, AB ;
Bareil, C ;
Schmidt, J ;
Luz, A ;
Pedersen, FS .
JOURNAL OF VIROLOGY, 1997, 71 (07) :5080-5087
[2]  
BAE SC, 1993, ONCOGENE, V8, P809
[3]   CLONING, MAPPING AND EXPRESSION OF PEBP2-ALPHA-C, A 3RD GENE ENCODING THE MAMMALIAN RUNT DOMAIN [J].
BAE, SC ;
TAKAHASHI, E ;
ZHANG, YW ;
OGAWA, E ;
SHIGESADA, K ;
NAMBA, Y ;
SATAKE, M ;
ITO, Y .
GENE, 1995, 159 (02) :245-248
[4]   VIRAL RNA-DEPENDENT DNA POLYMERASE - RNA-DEPENDENT DNA POLYMERASE IN VIRIONS OF RNA TUMOUR VIRUSES [J].
BALTIMORE, D .
NATURE, 1970, 226 (5252) :1209-+
[5]   ASSOCIATIONS BETWEEN MORPHOLOGY, KARYOTYPE, AND CLINICAL-FEATURES IN MYELOID LEUKEMIAS [J].
BITTER, MA ;
LEBEAU, MM ;
ROWLEY, JD ;
LARSON, RA ;
GOLOMB, HM ;
VARDIMAN, JW .
HUMAN PATHOLOGY, 1987, 18 (03) :211-225
[6]   IDENTIFICATION OF THE SL3-3 VIRUS ENHANCER CORE AS A T-LYMPHOMA CELL-SPECIFIC ELEMENT [J].
BORAL, AL ;
OKENQUIST, SA ;
LENZ, J .
JOURNAL OF VIROLOGY, 1989, 63 (01) :76-84
[7]  
BOWIE JU, 1989, J BIOL CHEM, V264, P7596
[8]   IDENTIFICATION OF A CRITICAL REGULATORY SITE IN THE HUMAN INTERLEUKIN-3 PROMOTER BY IN-VIVO FOOTPRINTING [J].
CAMERON, S ;
TAYLOR, DS ;
TEPAS, EC ;
SPECK, NA ;
MATHEYPREVOT, B .
BLOOD, 1994, 83 (10) :2851-2859
[9]   A 3' END FRAGMENT ENCOMPASSING THE TRANSCRIPTIONAL ENHANCERS OF NONDEFECTIVE FRIEND-VIRUS CONFERS ERYTHROLEUKEMOGENICITY ON MOLONEY LEUKEMIA-VIRUS [J].
CHATIS, PA ;
HOLLAND, CA ;
SILVER, JE ;
FREDERICKSON, TN ;
HOPKINS, N ;
HARTLEY, JW .
JOURNAL OF VIROLOGY, 1984, 52 (01) :248-254
[10]   ROLE FOR THE 3' END OF THE GENOME IN DETERMINING DISEASE SPECIFICITY OF FRIEND AND MOLONEY MURINE LEUKEMIA VIRUSES [J].
CHATIS, PA ;
HOLLAND, CA ;
HARTLEY, JW ;
ROWE, WP ;
HOPKINS, N .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA-BIOLOGICAL SCIENCES, 1983, 80 (14) :4408-4411